Drug Profile
Research programme: cancer immunotherapeutics - Atreca
Latest Information Update: 20 May 2021
Price :
$50
*
At a glance
- Originator Atreca
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 30 Apr 2021 The United States Patent and Trademark Office issues a Notice of Allowance for US patent application of Atreca’s Immune Repertoire Capture® technology
- 28 Apr 2020 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 31 May 2017 Atreca and Dana-Farber Cancer Institute collaborates to develop cancer immunotherapies using IRC™ technology in Cancer